Biotech Inscript

About Publications Sign in Subscribe

Former Google AI Expert's Biotech Start-Up Raises $100 Million for AI-Driven Drug Innovation

Former Google AI Expert's Biotech Start-Up Raises $100 Million for AI-Driven Drug Innovation

Inceptive, founded by a former Google AI expert, secures $100M in funding from investors like Nvidia and Andreessen Horowitz to advance AI-driven biotech initiatives

Top Stories

Roche to Acquire Carmot Therapeutics in a $3.1 Billion Deal

Roche to acquire Carmot Therapeutics for $3.1B, gaining access to innovative obesity and diabetes treatments. The deal includes clinical-stage assets with potential for standalone and combination therapies. Expected to close in Q1 2024, pending regulatory approval.

Samsung Biologics and VC Firm Kurma Partners Announce Biologics Manufacturing Partnership for Kurma's Portfolio Companies

Samsung Biologics & Kurma Partners team up for biologics development & manufacturing, empowering startups in Kurma's portfolio with tailored CMC services & global expertise. A strategic partnership driving biopharmaceutical innovation.

Edesa Biotech Secures C$23 Million Canadian Govt. Funding to Accelerate Breakthrough Immune Treatment

Edesa Biotech secures C$23 million in government funding for Phase 3 clinical study of EB05, a pioneering immune therapy, as announced in their press release. The funding reinforces their commitment to advancing healthcare innovation.

Latest

Newcastle University's Biotech Spinout MarraBio Raises £500,000 in Seed for Innovative Protein Tech

Newcastle University's Biotech Spinout MarraBio Raises £500,000 in Seed for Innovative Protein Tech

MarraBio, a Newcastle spinout from the university, secures £500,000 seed funding for cost-effective bioactive protein alternatives, with support from Maven Capital Partners, Northstar Ventures, CPI Enterprises, and TCS Biosciences, targeting biomedical research and cultivated meat markets.

Biocon Appoints Peter Bains as Group CEO to Drive Growth and Synergy

Biocon Ltd appoints Mr. Peter Bains as Group CEO, focusing on growth and synergy. He brings global biopharmaceutical expertise and a history with the Biocon Group, overseeing strategic leadership among its core businesses.

Axolotl Biologix and Carmell Therapeutics Merge to Pioneer Regenerative Medicine Advancements

Axolotl Biologix and Carmell Therapeutics Merge to Pioneer Regenerative Medicine Advancements

Flagstaff's Axolotl Biologix merges with Carmell Therapeutics, a major move in regenerative medicine. $65 million initial value with potential for $75 million more in milestone payments. Pioneering innovations expected in soft tissue repair and orthopedics.

Former Google AI Expert's Biotech Start-Up Raises $100 Million for AI-Driven Drug Innovation

Former Google AI Expert's Biotech Start-Up Raises $100 Million for AI-Driven Drug Innovation

Inceptive, founded by a former Google AI expert, secures $100M in funding from investors like Nvidia and Andreessen Horowitz to advance AI-driven biotech initiatives

University of Birmingham and Acticor Biotech Gain Regulatory Approval for Groundbreaking LIBERATE Clinical Study

University of Birmingham and Acticor Biotech Gain Regulatory Approval for Groundbreaking LIBERATE Clinical Study

Birmingham - September 9, 2023: In a momentous development for cardiovascular medicine, the University of Birmingham and Acticor Biotech have received full regulatory approval for the LIBERATE clinical study. This study marks a significant stride towards potential breakthroughs in the treatment of heart attacks, using the novel antithrombotic drug, glenzocimab.

The UK Unveils Ambitious Biomass Strategy, Gains Industry Applause

10 August 2023: The UK government has released its latest biomass strategy, focusing on detailing the country's plan to expand the cultivation of forestry and agricultural crops within its borders. This expansion aims to address the growing need for bioenergy. The Biomass Strategy outlines the actions planned by the government

Bioengineered Enzyme-Scissors Uncover New Pathways For Tackling Cancer Resistance

10 Aug, 2023: Scientists at Stanford University have developed a biomolecule that targets and eliminates mucins exclusively within cancer cells. This finding holds great promise for potential cancer treatments in the future. Mucins are protein molecules covered in sugar molecules, serving as a main line of defence against physical harm